FDA Approves Amivantamab-vmjw for Subset of NSCLC

On May 21, 2021, the U.S. Food and Drug Administration (FDA) approved mivantamab-vmjw as the first treatment for adult patients with non-small cell lung cancer (NSCLC) whose tumors have specific types of genetic mutations: epidermal growth factor receptor exon 20 insertion mutations.

Read the FDA announcement.

Posted 5/21/2021